MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

Taxane therapy remains the standard of care for triple-negative breast cancer. However, high frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer cells can acquire resistance to this drug. The actin regulatory protein MENA and particularly its invasive...

Full description

Bibliographic Details
Main Authors: Han, Sangyoon, Jonas, Oliver, Oudin, Madeleine Julie, Barbier, Lucie, Schafer, Claudia, Kosciuk, Tatsiana, Miller, Miles Aaron, Lauffenburger, Douglas A, Gertler, Frank
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Published: American Association for Cancer Research (AACR) 2018
Online Access:http://hdl.handle.net/1721.1/116423
https://orcid.org/0000-0001-6988-4260
https://orcid.org/0000-0002-0050-989X
https://orcid.org/0000-0003-3214-4554

Internet

http://hdl.handle.net/1721.1/116423
https://orcid.org/0000-0001-6988-4260
https://orcid.org/0000-0002-0050-989X
https://orcid.org/0000-0003-3214-4554

Similar Items